Chimeric Antigen Receptor and Car-T Cells That Bind Cxcr5

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to a novel chimeric antigen receptor (CAR) that specifically binds the human CXC chemokine receptor type 5 (CXCR5). The invention includes the design of an antibody-based CAR (including nucleic acid constructs) and the generation of genetically modified immune cells, preferably CAR-T cells, that can recognize and destroy cells expressing CXCR5. These CAR-T cells are intended for the treatment of diseases involving CXCR5-positive pathogenic cells, such as certain types of lymphomas (especially mature B cell non-Hodgkin's lymphoma), some autoimmune diseases, and possibly HIV reservoirs.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted immunotherapy for mature B cell non-Hodgkin’s lymphoma (B-NHL), including difficult-to-treat or relapsed cases.
• Treatment of other B cell lymphoproliferative disorders such as acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma, and diffuse large B cell lymphoma.
• Targeted therapy for T cell non-Hodgkin's lymphoma and other T cell lymphoproliferative disorders expressing CXCR5.
• Adoptive cell therapy for autoantibody-dependent autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis.
• Potential treatment of HIV infection by targeting CXCR5-positive T follicular helper cell reservoirs of the virus.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new therapeutic option for cancers and autoimmune diseases that express CXCR5, especially where current treatments fail or cause significant side effects.
• Effective against tumors or pathogenic cells even when traditional targets like CD19 are lost due to resistance or mutation.
• Spares normal hematopoietic cells, reducing off-target toxicity compared to existing CAR-T therapies.
• Applicable to patients who cannot tolerate chemotherapy or stem cell transplantation, such as elderly or fragile individuals.
• Can be used as a salvage therapy or as a bridging treatment before other interventions.
• High specificity and avidity for CXCR5 minimizes risk of harming healthy (CXCR5-negative) tissues.
• Flexible CAR design allows adaptation to different patient needs or disease circumstances.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.